Home > Dermatology > EADV 2020 > JAK Inhibitors – A Fascinating Novel Drug Class > JAK inhibitors in vitiligo

JAK inhibitors in vitiligo

Presented By
Dr Mehdi Rashighi, Massachusetts Medical School, USA
Conference
EADV 2020
A mouse-model study suggests that the IFNγ/CXCL10 axis plays a role in the pathogenesis of vitiligo. Moreover, a recently published proof-of-concept study showed that a cream containing the Janus kinase (JAK) inhibitor ruxolitinib is indeed effective in vitiligo [1,2]. Vitiligo patients have increased numbers of autoreactive, melanocyte-specific CD8+ T cells in their skin and blood, which are directly responsible for melanocyte destruction. In addition, gene expression in lesional skin from vitiligo patients revealed an IFNγ-specific signature, including the chemokine CXCL10. Experimental data in a mouse model identified a critical role for CXCL10 in both the progression and maintenance of vitiligo, thereby supporting inhibition of CXCL10 as a targeted treatment strategy for vitiligo patients [3]. Since IFNγ signal transduction occurs through JAK1 and 2, JAK inhibitors could lead to blockade of IFNγ signalling and downstream CXCL10 expression. I...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on